Adjuvant therapy with pegylated interferon alfa-2b (36 months) versus low-dose interferon alfa-2b (18 months) in melanoma patients without macrometastatic nodes: An open-label, randomised, phase 3 European Association for Dermato-Oncology (EADO) study

European Journal of Cancer

Volumn 49, Issue 1, 2013, Pages 166-174

  Grob, Jean Jacques ^a   Jouary, Thomas ^b   Dréno, Brigitte ^c   Asselineau, Julien ^d   Gutzmer, Ralf ^e   Hauschild, Axel ^f   Leccia, Marie Thérèse ^g   Landthaler, Michael ^h   Garbe, Claus ⁱ   Sassolas, Bruno ^j   Herbst, Rudolf A ^k   Guillot, Bernard ^l   Chene, Genevieve ^d   Pehamberger, Hubert ^m  

^a AIX MARSEILLE UNIVERSITY   (France)

^b HÔPITAL SAINT ANDRÉ   (France)

^c NANTES UNIVERSITY HOSPITAL   (France)

^d BORDEAUX UNIVERSITY HOSPITAL   (France)

^e HANNOVER MEDICAL SCHOOL   (Germany)

^f UNIVERSITY HOSPITAL SCHLESWIG HOLSTEIN   (Germany)

^g HÔPITAL MICHALLON   (France)

^h UNIVERSITY HOSPITAL REGENSBURG   (Germany)

ⁱ UNIVERSITY HOSPITAL TÜBINGEN   (Germany)

^j SERVICE DE RHUMATOLOGIE   (France)

^k HELIOS KLINIKUM ERFURT   (Germany)

^l HÔPITAL SAINT ELOI   (France)

^m Universitatsklinik fur Dermatologie   (Austria)

more..

Author keywords

Adjuvant drug therapy; Interferon alpha 2b; Melanoma; Peg interferon alpha 2b; Randomised control trial

Indexed keywords

ALPHA2B INTERFERON; PEGINTERFERON ALPHA2B;

ADULT; AGED; ARTICLE; AUSTRIA; CANCER ADJUVANT THERAPY; CANCER RECURRENCE; CANCER STAGING; CUTANEOUS MELANOMA; DEATH; DISEASE FREE SURVIVAL; DISTANT METASTASIS FREE SURVIVAL; DRUG DOSE REDUCTION; DRUG EFFICACY; DRUG WITHDRAWAL; FEMALE; FRANCE; GERMANY; HISTOPATHOLOGY; HUMAN; IN-TRANSIT METASTASIS; LOCAL METASTASIS; LOW DRUG DOSE; LYMPH NODE DISSECTION; LYMPH NODE METASTASIS; MAJOR CLINICAL STUDY; MALE; MULTICENTER STUDY; OPEN STUDY; OUTCOME ASSESSMENT; OVERALL SURVIVAL; PHASE 3 CLINICAL TRIAL; PHYSICAL EXAMINATION; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL; RECURRENCE RISK; RISK ASSESSMENT; SENTINEL LYMPH NODE; SENTINEL LYMPH NODE BIOPSY; TREATMENT DURATION; TUMOR VOLUME; ULCER; UNSPECIFIED SIDE EFFECT;

ADOLESCENT; ADULT; AGED; ANTINEOPLASTIC AGENTS; CHEMOTHERAPY, ADJUVANT; DISEASE-FREE SURVIVAL; FEMALE; HUMANS; INTERFERON-ALPHA; KAPLAN-MEIER ESTIMATE; LYMPHATIC METASTASIS; MALE; MELANOMA; MIDDLE AGED; NEOPLASM STAGING; POLYETHYLENE GLYCOLS; RECOMBINANT PROTEINS; SKIN NEOPLASMS; YOUNG ADULT;

EID: 84871408921     PISSN: 09598049     EISSN: 18790852     Source Type: Journal    
DOI: 10.1016/j.ejca.2012.07.018     Document Type: Article

References (16)

1. J.M. Kirkwood, M.H. Strawderman, and M.S. Ernstoff Interferon alfa-2b adjuvant therapy of high-risk resected cutaneous melanoma: the Eastern Cooperative Oncology Group Trial EST 1684 J Clin Oncol 14 1 1996 7 17 (Pubitemid 26019991)
2. J.J. Grob, B. Dreno, and P. de la Salmoniere Randomised trial of interferon alpha-2a as adjuvant therapy in resected primary melanoma thicker than 1.5 mm without clinically detectable node metastases. French Cooperative Group on Melanoma Lancet 351 9120 1998 1905 1910 (Pubitemid 28297445)
3. H. Pehamberger, H.P. Soyer, and A. Steiner Adjuvant interferon alfa-2a treatment in resected primary stage II cutaneous melanoma. Austrian Malignant Melanoma Cooperative Group J Clin Oncol 16 4 1998 1425 1429 (Pubitemid 28175761)
4. J.M. Kirkwood, J.G. Ibrahim, and V.K. Sondak High- and low-dose interferon alfa-2b in high-risk melanoma: first analysis of intergroup trial E1690/S9111/C9190 J Clin Oncol 18 12 2000 2444 2458 (Pubitemid 30415832)
5. A.M. Eggermont, S. Suciu, and R. MacKie Post-surgery adjuvant therapy with intermediate doses of interferon alfa 2b versus observation in patients with stage IIb/III melanoma (EORTC 18952): randomised controlled trial Lancet 366 9492 2005 1189 1196 (Pubitemid 41393597)
6. C. Garbe, P. Radny, and R. Linse Adjuvant low-dose interferon {alpha}2a with or without dacarbazine compared with surgery alone: a prospective- randomized phase III DeCOG trial in melanoma patients with regional lymph node metastasis Ann Oncol 19 6 2008 1195 1201 (Pubitemid 351796347)
7. K. Wheatley, N. Ives, and B. Hancock Does adjuvant interferon-α for high-risk melanoma provide a worthwhile benefit? A meta-analysis of the randomised trials Cancer Treat Rev 29 4 2003 241 252 (Pubitemid 37069655)
8. K. Wheatley, N. Ives, and A. Eggermont Interferon-α as adjuvant therapy for melanoma: an individual patient data meta-analysis of randomised trials J Clin Oncol (Meeting Abstracts) 25 18 suppl 2007 8526
9. S. Mocellin, S. Pasquali, C.R. Rossi, and D. Nitti Interferon alpha adjuvant therapy in patients with high-risk melanoma: a systematic review and meta-analysis J Natl Cancer Inst 102 7 2010 493 501
10. C. Garbe, K. Peris, and A. Hauschild Diagnosis and treatment of melanoma: European consensus-based interdisciplinary guideline Eur J Cancer 46 2 2010 270 283
11. A. Hauschild, M. Weichenthal, and K. Rass Efficacy of low-dose interferon {alpha}2a 18 versus 60 months of treatment in patients with primary melanoma of ≥1.5 mm tumor thickness: results of a randomized phase III DeCOG trial J Clin Oncol 28 5 2010 841 846
12. R. Bukowski, M.S. Ernstoff, and M.E. Gore Pegylated interferon alfa-2b treatment for patients with solid tumors: a phase I/II study J Clin Oncol 20 18 2002 3841 3849
13. A.M. Eggermont, S. Suciu, and M. Santinami Adjuvant therapy with pegylated interferon alfa-2b versus observation alone in resected stage III melanoma: final results of EORTC 18991, a randomised phase III trial Lancet 372 9633 2008 117 126 (Pubitemid 351952257)
14. A.B. Miller, B. Hoogstraten, M. Staquet, and A. Winkler Reporting results of cancer treatment Cancer 47 1 1981 207 214 (Pubitemid 11167383)
15. Y. Brandberg, S. Aamdal, and L. Bastholt Health-related quality of life in patients with high-risk melanoma randomised in the Nordic phase 3 trial with adjuvant intermediate-dose interferon alfa-2b Eur J Cancer 2011 Dec 22
16. C. Loquai, I. Schmidtmann, and M. Beutel Quality of life in melanoma patients during adjuvant treatment with pegylated interferon-2b: patients' and doctors' views Eur J Dermatol 21 6 2011 976 984